Compare Meta Platforms Inc (META) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Novartis AG — how do they compare? Meta Platforms Inc trades at $721.74 (market cap $1.84T), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Meta Platforms Inc is far larger — about 6.7× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and Novartis AG for 82 Days on average.
| META | NVS | |
|---|---|---|
Market Cap | $1.84T | $274.00B |
Volume | 12,743,601 | 1,852,137 |
Sector | Media | Health |
52-Week High | $777.59 | $168.62 |
52-Week Low | $525.72 | $121.80 |
Typical Hold Time | 127 Days | 82 Days |
Enterprise Value | $1.86T | $315.32B |
Dividend Yield | 0.29% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $720.89, down 2.43% on the day, with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with $201B revenue in 2025 and 29.8% net income margin, though Q2 2026 earnings missed expectations. Recent AI developments including the Muse Spark launch and a $21B partnership with CoreWeave highlight growth initiatives. Analyst consensus remains strongly bullish with 80% buy ratings and a $781 price target.
Meta presents a compelling investment case with strong profitability metrics and AI-driven growth potential, though faces regulatory risks from ongoing litigation and significant capital expenditure requirements. The stock's current valuation at 27x P/E appears reasonable given growth prospects, but investors should monitor execution on AI monetization and legal developments that could impact future earnings.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
